# C_2020367EN.01000101.xml

| 30.10.2020 | EN | Official Journal of the European Union | C 367/1 |
| --- | --- | --- | --- |

30.10.2020

EN

Official Journal of the European Union

C 367/1

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 January 2020 to 31 August 2020

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2020/C 367/01)

—   Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | INN (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 20.5.2020 | Zeposia | ozanimod | Celgene Europe B.V. |
| Winthontlaan 6 N, 3526 KV Utrecht, Nederland |

Date of the decision

Name of the medicinal product

INN (International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code (Anatomical Therapeutic Chemical Code)

Date of notification

20.5.2020

Zeposia

ozanimod

Celgene Europe B.V.

Winthontlaan 6 N, 3526 KV Utrecht, Nederland

EU/1/20/1442

Capsule, hard

L04AA38

25.5.2020

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 17.4.2020 | Natpar | Shire Pharmaceuticals Ireland Limited |
| Blocks 2 & 3 Miesian Plaza, 50 — 58 Baggot Street Lower, Dublin 2, Ireland |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

17.4.2020

Natpar

Shire Pharmaceuticals Ireland Limited

Blocks 2 & 3 Miesian Plaza, 50 — 58 Baggot Street Lower, Dublin 2, Ireland

EU/1/15/1078

20.5.2020

23.4.2020

Cyanokit

| SERB S.A. |
| --- |
| Avenue Louise 480, 1050 Bruxelles, Belgique/Louizalaan 480, 1050 Brussel, België |

SERB S.A.

Avenue Louise 480, 1050 Bruxelles, Belgique/Louizalaan 480, 1050 Brussel, België

EU/1/07/420

12.5.2020

23.4.2020

Oncaspar

| Les Laboratoires Servier |
| --- |
| 50 rue Carnot, 92284 Suresnes Cedex, France |

Les Laboratoires Servier

50 rue Carnot, 92284 Suresnes Cedex, France

EU/1/15/1070

13.5.2020

28.4.2020

Miglustat Gen.Orph

| Gen.Orph |
| --- |
| 185 Bureaux de la Colline, 92213 Saint Cloud Cedex, France |

Gen.Orph

185 Bureaux de la Colline, 92213 Saint Cloud Cedex, France

EU/1/17/1232

4.6.2002

28.4.2020

NeuroBloc

| Sloan Pharma S.a.r.l. |
| --- |
| 33 Rue de Puits Romain, 8070 Bertrange, Luxembourg |

Sloan Pharma S.a.r.l.

33 Rue de Puits Romain, 8070 Bertrange, Luxembourg

EU/1/00/166

19.5.2020

28.4.2020

Privigen

| CSL Behring GmbH |
| --- |
| Emil-von-Behring-Straße 76, 35041 Marburg, Deutschland |

CSL Behring GmbH

Emil-von-Behring-Straße 76, 35041 Marburg, Deutschland

EU/1/08/446

20.5.2020

22.6.2020

Avonex

| Biogen Netherlands B.V. |
| --- |
| Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland |

Biogen Netherlands B.V.

Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland

EU/1/97/033

17.7.2020

25.6.2020

Emtricitabine/Tenofovir disoproxil Krka d.d.

| KRKA d d., Novo mesto |
| --- |
| Šmarješka cesta 6, 8501 Novo mesto, Slovenija |

KRKA d d., Novo mesto

Šmarješka cesta 6, 8501 Novo mesto, Slovenija

EU/1/17/1182

20.7.2020

17.7.2020

Jentadueto

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |

Boehringer Ingelheim International GmbH

Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland

EU/1/12/780

27.7.2020

17.7.2020

Zarzio

| Sandoz GmbH |
| --- |
| Biochemiestrasse 10, 6250 Kundl, Österreich |

Sandoz GmbH

Biochemiestrasse 10, 6250 Kundl, Österreich

EU/1/08/495

17.8.2020

27.7.2020

TOBI Podhaler

| Mylan IRE Healthcare Ltd |
| --- |
| Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland |

Mylan IRE Healthcare Ltd

Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland

EU/1/10/652

29.7.2020

31.7.2020

CABOMETYX

| Ipsen Pharma |
| --- |
| 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France |

Ipsen Pharma

65 quai Georges Gorse, 92100 Boulogne-Billancourt, France

EU/1/16/1136

6.8.2020

31.7.2020

Oprymea

| KRKA d d., Novo mesto |
| --- |
| Šmarješka cesta 6, 8501 Novo mesto, Slovenija |

KRKA d d., Novo mesto

Šmarješka cesta 6, 8501 Novo mesto, Slovenija

EU/1/08/469

13.8.2020

28.8.2020

Effentora

| Teva B.V. |
| --- |
| Swensweg 5, 2031 GA Haarlem, Nederland |

Teva B.V.

Swensweg 5, 2031 GA Haarlem, Nederland

EU/1/08/441

7.9.2020

28.8.2020

Olanzapine Glenmark

| Glenmark Arzneimittel GmbH |
| --- |
| Industriestr. 31, D — 82194 Gröbenzell, Deutschland |

Glenmark Arzneimittel GmbH

Industriestr. 31, D — 82194 Gröbenzell, Deutschland

EU/1/09/587

9.9.2020

28.8.2020

Olanzapine Glenmark Europe

| Glenmark Arzneimittel GmbH |
| --- |
| Industriestr. 31, D — 82194 Gröbenzell, Deutschland |

Glenmark Arzneimittel GmbH

Industriestr. 31, D — 82194 Gröbenzell, Deutschland

EU/1/09/588

9.9.2020

—   Suspension of a marketing authorization (Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 25.3.2020 | Ulipristal Acetate Gedeon Richter | Gedeon Richter Plc. |
| Gyömrői út 19-21., 1103 Budapest, Magyarország |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

25.3.2020

Ulipristal Acetate Gedeon Richter

Gedeon Richter Plc.

Gyömrői út 19-21., 1103 Budapest, Magyarország

EU/1/18/1309

27.3.2020

—   Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 24.4.2020 | Suprelorin | VIRBAC S.A. |
| 1ère Avenue — 2065 m — L.I.D., 06516 Carros Cedex, France |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

24.4.2020

Suprelorin

VIRBAC S.A.

1ère Avenue — 2065 m — L.I.D., 06516 Carros Cedex, France

EU/2/07/072

20.5.2020

24.6.2020

Novaquin

| Le Vet Beheer B.V. |
| --- |
| Wilgenweg 7, 3421 TV Oudewater, Nederland |

Le Vet Beheer B.V.

Wilgenweg 7, 3421 TV Oudewater, Nederland

EU/2/15/186

20.7.2020

28.8.2020

Syvazul BTV

| LABORATORIOS SYVA, S.A.U. |
| --- |
| Av. Párroco Pablo Diez 49-57, 24010 León, España |

LABORATORIOS SYVA, S.A.U.

Av. Párroco Pablo Diez 49-57, 24010 León, España

EU/2/18/231

7.9.2020

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  OJ L 136, 30.4.2004, p. 1.

---